Close Asset Management’s Stoke Therapeutics STOK Stock Holding History

Close Asset Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	–	–	223
2021 Q1	$0	Buy	+4	New	+$228	﹤0.01%	225

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Close Asset Management's STOK Position: Q2 2021 in Review

Close Asset Management sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 4 shares.

Close Asset Management first reported a position in STOK in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

Close Asset Management reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
Close Asset Management sold 4 Stoke Therapeutics shares in Q2 2021.
Close Asset Management first reported a position in Stoke Therapeutics in Q1 2021 and held it in 1 quarter.
Close Asset Management's Stoke Therapeutics position peaked at $0 in Q1 2021.
97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Close Asset Management's 13F filing for Q2 2021, filed 27 Jul 2021.